PDCD1 and neoplasm: Preclinical studies in two murine models of solid tumors showed that loss of Ptdss1 in tumor cells and pharmacologic inhibition of Ptdss1 worked synergistically with anti–PD-1 treatment for improved antitumor response and survival.